A phase I study of dasatinib with concurrent chemoradiation for stage III non-small cell lung cancer

Frontiers in Oncology

Volumn 2 MAY, Issue , 2012, Pages

  Khurshid, Humera ^a   Dipetrillo, Thomas ^a   Ng, Thomas ^a   Mantripragada, Kalyan ^a   Birnbaum, Ariel ^a   Berz, David ^a   Radie Keane, Kathy ^a   Perez, Kimberly ^a   Constantinou, Maria ^a   Luppe, Denise ^a   Schumacher, Andrew ^a   Leonard, Kara ^a   Safran, Howard ^a  

^a Brown University Oncology Group   (United States)

Author keywords

Dasatinib; Lung cancer; Radiation; Src

Indexed keywords

CARBOPLATIN; DASATINIB; DEXAMETHASONE; DIPHENHYDRAMINE; PACLITAXEL; PREDNISONE; RANITIDINE;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BRONCHOSCOPY; CANCER STAGING; CHEMORADIOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DEHYDRATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DYSPHAGIA; DYSPNEA; ESOPHAGITIS; FATIGUE; FEMALE; FOLLOW UP; HEART MUSCLE ISCHEMIA; HEARTBURN; HUMAN; HYPOTENSION; INFECTION; LUNG DISEASE; LUNG NON SMALL CELL CANCER; MALE; NAUSEA AND VOMITING; NEUTROPENIA; PERICARDIAL EFFUSION; PHASE 1 CLINICAL TRIAL; PNEUMONIA; RADIATION DOSE; SURVIVAL; THORAX PAIN; TREATMENT RESPONSE; VERY ELDERLY;

EID: 84880711680     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2012.00056     Document Type: Article

References (19)

1. Bergeron, A., Réa, D., Levy, V., Picard, C., Meignin, V., Tamburini, J., Bruzzoni-Giovanelli, H., Calvo, F., Tazi, A., and Rousselot, P. (2007). Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. Am. J. Respir. Crit. Care Med. 176, 814-818.
2. Bradley, J. D., Paulus, R., Komaki, R., Masters, G., Forster, K., Schild, S. E., Bogart, J. A., Garces, Y. I., Narayan, S., and Choy, H. (2011). "Randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 GY) conformal chemoradiotherapy with or without cetuximab for stage IIIA/IIIB non-small cell lung cancer: preliminary findings on radiation dose in RTOG 0617," in 53rd ASTRO Annual Meeting, Miami Beach.
3. Dittmann, K., Mayer, C., Kehlbach, R., Rothmund, M. C., and Peter Rodemann, H. (2009). Radiation-induced lipid peroxidation activates src kinase and triggers nuclear EGFR transport. Radiother. Oncol. 92, 379-382.
4. Dumitrescu, D., Seck, C., ten Freyhaus, H., Gerhardt, F., Erdmann, E., and Rosenkranz, S. (2011). Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukaemia. Eur. Respir. J. 38, 218-220.
5. Hanna, N., Neubauer, M., Yiannoutsos, C., McGarry, R., Arseneau, J., Ansari, R., Reynolds, C., Govindan, R., Melnyk, A., Fisher, W., Richards, D., Bruetman, D., Anderson, T., Chowhan, N., Nattam, S., Mantravadi, P., Johnson, C., Breen, T., White, A., and Einhorn, L. (2008). Phase III study of cisplatin, etoposide and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J. Clin. Oncol. 26, 5755-5760.
6. Haura, E. B., Tanvetyanon, T., Chiappori, A., Williams, C., Simon, G., Antonia, S., Gray, J., Litschauer, S., Tetteh, L., Neuger, A., Song, L., Rawal, B., Schell, M. J., and Bepler, G. (2010). Phase I/II study of the src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J. Clin. Oncol. 28, 1387-1394.
7. Johnson, F. M., Bekele, B. N., Feng, L., Wistuba, I., Tang, X. M., Tran, H. T., Erasmus, J. J., Hwang, L. L., Takebe, N., Blumenschein, G. R., Lippman, S. M., and Stewart, D. J. (2010). Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 28, 4609-4615.
8. Kelly, K., Chansky, K., Gaspar, L. E., Albain, K. S., Jett, J., Ung, Y. C., Lau, D. H., Crowley, J. J., and Gandara, D. R. (2008). Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small cell lung cancer. J. Clin. Oncol. 26, 2450-2456.
9. Khan, E. M., Heidinger, J. M., Levy, M., Lisanti, M. P., Ravid, T., and Goldkorn, T. (2006). Epidermal growth factor receptor exposed to oxidative stress undergoes Src-and caveolin-1-dependent perinuclear trafficking. J. Biol. Chem. 281, 14486-14493.
10. Kim, L. C., Song, L., and Haura, E. B. (2009). Src kinases as therapeutic targets for cancer. Nat. Rev. Clin. Oncol. 6, 587-595.
11. Masaki, T., Igarashi, K., Tokuda, M., Yukimasa, S., Han, F., Jin, Y. J., Li, J. Q., Yoneyama, H., Uchida, N., Fujita, J., Yoshiji, H., Watanabe, S., Kurokohchi, K., and Kuriyama, S. (2003). pp60c-src activation in lung adenocarcinoma. Eur. J. Cancer 39, 1447-1455.
12. Mattei, D., Feola, M., Orzan, F., Mordini, N., Rapezzi, D., and Gallamini, A. (2009). Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient. Bone Marrow Transplant. 43, 967-968.
13. Orlandi, E. M., Rocca, B., Pazzano, A. S., and Ghio, S. (2012). Reversible pulmonary arterial hypertension likely related to long-term, low-dose dasatinib treatment for chronic myeloid leukemia. Leuk. Res. 36, e4-e6.
14. Purnell, P. R., Mack, P. C., Tepper, C. G., Evans, C. P., Green, T. P., Gumerlock, P. H., Lara, P. N., Gandara, D. R., Kung, H. J., and Gautschi, O. (2009). The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells. J. Thorac. Oncol. 4, 448-454.
15. Rasheed, W., Flaim, B., and Seymour, J. F. (2009). Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia. Leuk. Res. 33, 861-864.
16. Schmidt-Ullrich, R. K., Mikkelsen, R. B., Dent, P., Todd, D. G., Valerie, K., Kavanagh, B. D., Contessa, J. N., Rorrer, W. K., and Chen, P. B. (1997). Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene 15, 1191-1197.
17. Shah, N. P., Kantarjian, H. M., Kim, D. W., Réa, D., Dorlhiac-Llacer, P. E., Milone, J. H., Vela-Ojeda, J., Silver, R. T., Khoury, H. J., Charbonnier, A., Khoroshko, N., Paquette, R. L., Deininger, M., Collins, R. H., Otero, I., Hughes, T., Bleickardt, E., Strauss, L., Francis, S., and Hochhaus, A. (2008). Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and intolerant chronic-phase chronic myeloid leukemia. J. Clin. Oncol. 26, 3204-3212.
18. Vokes, E. E., Herndon, J. E. II, Kelley, M. J., Cicchetti, M. G., Ramnath, N., Neill, H., Atkins, J. N., Watson, D. M., Akerley, W., and Green, M. R. (2007). Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: cancer and leukemia group B. J. Clin. Oncol. 25, 1698-1704.
19. Zhang, J., Kalyankrishna, S., Wislez, M., Thilaganathan, N., Saigal, B., Wei, W., Ma, L., Wistuba, I. I., Johnson, F. M., and Kurie, J. M. (2007). SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines. Am. J. Pathol. 170, 366-376.